Tag: Isocitrate Dehydrogenase (IDH) Inhibitors Market

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Isocitrate Dehydrogenase (IDH) Inhibitors Market Revenue Growth On Track For A 26.6% CAGR Through 2030

The market size for isocitrate dehydrogenase (idh) inhibitors has experienced significant growth in recent years. It is projected to expand from $2.46 billion in 2025 to $3.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 26.8%. This historical growth can be attributed to several factors, including advancements in cancer genomics research, the urgent unmet needs in oncology, the emergence of mutation-driven drug discovery, broader hospital oncology adoption, and an increase in clinical trial expansion.

The isocitrate dehydrogenase (idh) inhibitors market size is anticipated to experience substantial growth over the next few years, with projections indicating it will expand to $8.02 billion in 2030 at a compound annual growth rate (CAGR) of 26.6%. This expected expansion during the forecast period is driven by progress in precision medicine, the rise of biomarker-driven oncology care, robust rare cancer drug pipelines, the development of combination cancer therapies, and regulatory backing for targeted drugs. Significant trends in the coming period encompass the broadening of targeted oncology therapies, increased drug development based on genetic mutations, an intensifying focus on treatments for rare cancers, the growing utilization of precision oncology diagnostics, and ongoing advancements in small molecule cancer inhibitors.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=89123041&type=smp&name=Isocitrate%20Dehydrogenase%20%28IDH%29%20Inhibitors%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Isocitrate Dehydrogenase (IDH) Inhibitors Market Development Factors: What’s Supporting Demand?

The rising incidence of acute myeloid leukemia is anticipated to fuel the expansion of the isocitrate dehydrogenase (IDH) inhibitors market. Acute myeloid leukemia (AML) is characterized as a rapidly progressing cancer affecting the blood and bone marrow, marked by the swift generation of abnormal white blood cells that impede normal blood cell formation. This increased occurrence of AML is linked to an expanding aging population, as older individuals face a heightened risk of developing this aggressive blood cancer due to age-related changes in their bone marrow and immune system. Isocitrate dehydrogenase (IDH) inhibitors effectively treat acute myeloid leukemia by blocking mutant IDH enzymes, which helps restore typical blood cell development and decelerates the proliferation of leukemia cells. For instance, in February 2023, a report from the Leukaemia Foundation, an Australia-based non-profit organization, indicated that between 2022 and 2035, more than 7,000 children, 6,000 young adults, and 108,000 adults aged 25–65 are expected to be diagnosed with various blood cancers, primarily acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). Consequently, the growing frequency of acute myeloid leukemia is projected to propel the growth of the isocitrate dehydrogenase (IDH) inhibitors market.

Isocitrate Dehydrogenase (IDH) Inhibitors Market Segment Analysis And Revenue Potential

The isocitrate dehydrogenase (idh) inhibitors market covered in this report is segmented –

1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types

2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types

3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical

4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications

Subsegments:

1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma

2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)

3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers

Isocitrate Dehydrogenase (IDH) Inhibitors Market Transformation Trends: What Innovations Are Driving Change?

Key companies operating in the isocitrate dehydrogenase (IDH) inhibitors market are heavily focused on securing regulatory approvals. This strategic emphasis aims to broaden the clinical applications of their therapies, accelerate their entry into the market, and achieve a competitive advantage in the treatment of IDH-mutant cancers. Regulatory approvals are formal permissions granted by health authorities, enabling a drug to be marketed and utilized after its safety and effectiveness have been confirmed. For instance, in August 2024, Servier Laboratoires, a pharmaceutical company based in France, received FDA approval for VORANIGO (vorasidenib) tablets. This approval designates it as the first targeted therapy for patients diagnosed with Grade 2 IDH-mutant glioma, including astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. This oral treatment significantly extends progression-free survival, a finding from the Phase 3 INDIGO trial, where patients experienced a median progression-free survival of 27.7 months compared to 11.1 months for the placebo group. VORANIGO provides a convenient and well-tolerated treatment choice with manageable side effects, representing a major therapeutic advancement for patients who previously had limited options.

Isocitrate Dehydrogenase (IDH) Inhibitors Market Key Players Shaping Industry Direction

Major companies operating in the isocitrate dehydrogenase (idh) inhibitors market are Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology Inc., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC

View The Full Isocitrate Dehydrogenase (IDH) Inhibitors Market Report:

https://thebusinessresearchcompany.com/report/isocitrate-dehydrogenase-idh-inhibitors-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Isocitrate Dehydrogenase (IDH) Inhibitors Market Regional Analysis And Leading Geography

North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (idh) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Isocitrate Dehydrogenase (IDH) Inhibitors Market Revenue Growth On Track For A 26.6% CAGR Through 2030

The market size for isocitrate dehydrogenase (idh) inhibitors has experienced significant growth in recent years. It is projected to expand from $2.46 billion in 2025 to $3.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 26.8%. This historical growth can be attributed to several factors, including advancements in cancer genomics research, the urgent unmet needs in oncology, the emergence of mutation-driven drug discovery, broader hospital oncology adoption, and an increase in clinical trial expansion.

The isocitrate dehydrogenase (idh) inhibitors market size is anticipated to experience substantial growth over the next few years, with projections indicating it will expand to $8.02 billion in 2030 at a compound annual growth rate (CAGR) of 26.6%. This expected expansion during the forecast period is driven by progress in precision medicine, the rise of biomarker-driven oncology care, robust rare cancer drug pipelines, the development of combination cancer therapies, and regulatory backing for targeted drugs. Significant trends in the coming period encompass the broadening of targeted oncology therapies, increased drug development based on genetic mutations, an intensifying focus on treatments for rare cancers, the growing utilization of precision oncology diagnostics, and ongoing advancements in small molecule cancer inhibitors.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=89123041&type=smp&name=Isocitrate%20Dehydrogenase%20%28IDH%29%20Inhibitors%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Isocitrate Dehydrogenase (IDH) Inhibitors Market Development Factors: What’s Supporting Demand?

The rising incidence of acute myeloid leukemia is anticipated to fuel the expansion of the isocitrate dehydrogenase (IDH) inhibitors market. Acute myeloid leukemia (AML) is characterized as a rapidly progressing cancer affecting the blood and bone marrow, marked by the swift generation of abnormal white blood cells that impede normal blood cell formation. This increased occurrence of AML is linked to an expanding aging population, as older individuals face a heightened risk of developing this aggressive blood cancer due to age-related changes in their bone marrow and immune system. Isocitrate dehydrogenase (IDH) inhibitors effectively treat acute myeloid leukemia by blocking mutant IDH enzymes, which helps restore typical blood cell development and decelerates the proliferation of leukemia cells. For instance, in February 2023, a report from the Leukaemia Foundation, an Australia-based non-profit organization, indicated that between 2022 and 2035, more than 7,000 children, 6,000 young adults, and 108,000 adults aged 25–65 are expected to be diagnosed with various blood cancers, primarily acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). Consequently, the growing frequency of acute myeloid leukemia is projected to propel the growth of the isocitrate dehydrogenase (IDH) inhibitors market.

Isocitrate Dehydrogenase (IDH) Inhibitors Market Segment Analysis And Revenue Potential

The isocitrate dehydrogenase (idh) inhibitors market covered in this report is segmented –

1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types

2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types

3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical

4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications

Subsegments:

1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma

2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)

3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers

Isocitrate Dehydrogenase (IDH) Inhibitors Market Transformation Trends: What Innovations Are Driving Change?

Key companies operating in the isocitrate dehydrogenase (IDH) inhibitors market are heavily focused on securing regulatory approvals. This strategic emphasis aims to broaden the clinical applications of their therapies, accelerate their entry into the market, and achieve a competitive advantage in the treatment of IDH-mutant cancers. Regulatory approvals are formal permissions granted by health authorities, enabling a drug to be marketed and utilized after its safety and effectiveness have been confirmed. For instance, in August 2024, Servier Laboratoires, a pharmaceutical company based in France, received FDA approval for VORANIGO (vorasidenib) tablets. This approval designates it as the first targeted therapy for patients diagnosed with Grade 2 IDH-mutant glioma, including astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. This oral treatment significantly extends progression-free survival, a finding from the Phase 3 INDIGO trial, where patients experienced a median progression-free survival of 27.7 months compared to 11.1 months for the placebo group. VORANIGO provides a convenient and well-tolerated treatment choice with manageable side effects, representing a major therapeutic advancement for patients who previously had limited options.

Isocitrate Dehydrogenase (IDH) Inhibitors Market Key Players Shaping Industry Direction

Major companies operating in the isocitrate dehydrogenase (idh) inhibitors market are Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology Inc., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC

View The Full Isocitrate Dehydrogenase (IDH) Inhibitors Market Report:

https://thebusinessresearchcompany.com/report/isocitrate-dehydrogenase-idh-inhibitors-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Isocitrate Dehydrogenase (IDH) Inhibitors Market Regional Analysis And Leading Geography

North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (idh) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Isocitrate Dehydrogenase (IDH) Inhibitors Market Revenue Growth On Track For A 26.6% CAGR Through 2030

The market size for isocitrate dehydrogenase (idh) inhibitors has experienced significant growth in recent years. It is projected to expand from $2.46 billion in 2025 to $3.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 26.8%. This historical growth can be attributed to several factors, including advancements in cancer genomics research, the urgent unmet needs in oncology, the emergence of mutation-driven drug discovery, broader hospital oncology adoption, and an increase in clinical trial expansion.

The isocitrate dehydrogenase (idh) inhibitors market size is anticipated to experience substantial growth over the next few years, with projections indicating it will expand to $8.02 billion in 2030 at a compound annual growth rate (CAGR) of 26.6%. This expected expansion during the forecast period is driven by progress in precision medicine, the rise of biomarker-driven oncology care, robust rare cancer drug pipelines, the development of combination cancer therapies, and regulatory backing for targeted drugs. Significant trends in the coming period encompass the broadening of targeted oncology therapies, increased drug development based on genetic mutations, an intensifying focus on treatments for rare cancers, the growing utilization of precision oncology diagnostics, and ongoing advancements in small molecule cancer inhibitors.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=89123041&type=smp&name=Isocitrate%20Dehydrogenase%20%28IDH%29%20Inhibitors%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Isocitrate Dehydrogenase (IDH) Inhibitors Market Development Factors: What’s Supporting Demand?

The rising incidence of acute myeloid leukemia is anticipated to fuel the expansion of the isocitrate dehydrogenase (IDH) inhibitors market. Acute myeloid leukemia (AML) is characterized as a rapidly progressing cancer affecting the blood and bone marrow, marked by the swift generation of abnormal white blood cells that impede normal blood cell formation. This increased occurrence of AML is linked to an expanding aging population, as older individuals face a heightened risk of developing this aggressive blood cancer due to age-related changes in their bone marrow and immune system. Isocitrate dehydrogenase (IDH) inhibitors effectively treat acute myeloid leukemia by blocking mutant IDH enzymes, which helps restore typical blood cell development and decelerates the proliferation of leukemia cells. For instance, in February 2023, a report from the Leukaemia Foundation, an Australia-based non-profit organization, indicated that between 2022 and 2035, more than 7,000 children, 6,000 young adults, and 108,000 adults aged 25–65 are expected to be diagnosed with various blood cancers, primarily acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). Consequently, the growing frequency of acute myeloid leukemia is projected to propel the growth of the isocitrate dehydrogenase (IDH) inhibitors market.

Isocitrate Dehydrogenase (IDH) Inhibitors Market Segment Analysis And Revenue Potential

The isocitrate dehydrogenase (idh) inhibitors market covered in this report is segmented –

1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types

2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types

3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical

4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications

Subsegments:

1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma

2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)

3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers

Isocitrate Dehydrogenase (IDH) Inhibitors Market Transformation Trends: What Innovations Are Driving Change?

Key companies operating in the isocitrate dehydrogenase (IDH) inhibitors market are heavily focused on securing regulatory approvals. This strategic emphasis aims to broaden the clinical applications of their therapies, accelerate their entry into the market, and achieve a competitive advantage in the treatment of IDH-mutant cancers. Regulatory approvals are formal permissions granted by health authorities, enabling a drug to be marketed and utilized after its safety and effectiveness have been confirmed. For instance, in August 2024, Servier Laboratoires, a pharmaceutical company based in France, received FDA approval for VORANIGO (vorasidenib) tablets. This approval designates it as the first targeted therapy for patients diagnosed with Grade 2 IDH-mutant glioma, including astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. This oral treatment significantly extends progression-free survival, a finding from the Phase 3 INDIGO trial, where patients experienced a median progression-free survival of 27.7 months compared to 11.1 months for the placebo group. VORANIGO provides a convenient and well-tolerated treatment choice with manageable side effects, representing a major therapeutic advancement for patients who previously had limited options.

Isocitrate Dehydrogenase (IDH) Inhibitors Market Key Players Shaping Industry Direction

Major companies operating in the isocitrate dehydrogenase (idh) inhibitors market are Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology Inc., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC

View The Full Isocitrate Dehydrogenase (IDH) Inhibitors Market Report:

https://thebusinessresearchcompany.com/report/isocitrate-dehydrogenase-idh-inhibitors-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Isocitrate Dehydrogenase (IDH) Inhibitors Market Regional Analysis And Leading Geography

North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (idh) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Isocitrate Dehydrogenase (IDH) Inhibitors Market Revenue Outlook: What CAGR Is Expected Through 2030?

The market for isocitrate dehydrogenase (IDH) inhibitors has seen exponential expansion in recent years, with projections indicating growth from $2.46 billion in 2025 to $3.13 billion in 2026, reflecting a compound annual growth rate (CAGR) of 26.8%. Historically, this upward trajectory has been propelled by advancements in cancer genomics research, persistent unmet needs in oncology, drug discovery efforts focused on specific mutations, integration of these therapies into hospital oncology practices, and an increase in clinical trial activities.

The isocitrate dehydrogenase (IDH) inhibitors market is poised for remarkable expansion over the coming years. By 2030, it is projected to reach a value of $8.02 billion, reflecting a compound annual growth rate (CAGR) of 26.6%. This forecasted growth is driven by several key factors, including progress in precision medicine, the rise of biomarker-driven oncology care, development of drugs targeting rare cancers, use of combination cancer therapies, and a favorable regulatory environment for targeted treatments. Looking ahead, major industry trends encompass the broadening of targeted oncology therapies, a greater emphasis on drug development based on genetic mutations, an increasing focus on treating rare cancers, wider adoption of precision oncology diagnostics, and continued innovation in small molecule cancer inhibitors.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24577&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Isocitrate Dehydrogenase (IDH) Inhibitors Market Growth Drivers And Industry Catalysts

The rising occurrence of acute myeloid leukemia is anticipated to drive expansion in the isocitrate dehydrogenase (IDH) inhibitors market moving forward. Acute myeloid leukemia (AML) is a rapidly progressing cancer affecting the blood and bone marrow, marked by the swift proliferation of abnormal white blood cells that disrupt normal blood cell production. This increase in AML cases is largely attributed to the growing elderly population, as older individuals face a heightened risk of developing this aggressive blood cancer due to age-related changes in their bone marrow and immune function. Isocitrate dehydrogenase (IDH) inhibitors are used to treat AML by blocking mutant IDH enzymes, thereby restoring normal blood cell development and slowing the proliferation of leukemia cells. For example, in February 2023, a report from the Leukaemia Foundation, an Australian non-profit organization, projected that between 2022 and 2035, over 7,000 children, 6,000 young adults, and 108,000 adults aged 25–65 will be diagnosed with blood cancers, primarily acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). Consequently, the growing frequency of acute myeloid leukemia is expected to fuel the growth of the isocitrate dehydrogenase (IDH) inhibitors market.

Isocitrate Dehydrogenase (IDH) Inhibitors Market Categorization By Product Type And Application

The isocitrate dehydrogenase (idh) inhibitors market covered in this report is segmented –

1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types

2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types

3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical

4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications

Subsegments:

1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma

2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)

3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers

Isocitrate Dehydrogenase (IDH) Inhibitors Market Trends Influencing Long-Term Demand

Leading pharmaceutical firms in the isocitrate dehydrogenase (IDH) inhibitor market are concentrating their efforts on securing regulatory approvals to broaden the therapeutic applications of their products, speed up market introduction, and establish a competitive edge in addressing IDH-mutant cancers. These approvals are official endorsements from health authorities that permit the commercialization and use of a drug following rigorous verification of its safety and efficacy. As a case in point, in August 2024, Servier Laboratoires, a pharmaceutical company headquartered in France, secured FDA clearance for VORANIGO (vorasidenib) tablets as the first targeted treatment for individuals with Grade 2 IDH-mutant glioma, encompassing astrocytoma and oligodendroglioma that harbor IDH1 or IDH2 mutations. This oral medication notably extends progression-free survival, as evidenced by the Phase 3 INDIGO trial, where participants achieved a median progression-free survival of 27.7 months, compared to 11.1 months for those receiving a placebo. VORANIGO provides a convenient and well-tolerated therapeutic option with manageable adverse effects, representing a major milestone for a population that previously faced limited treatment alternatives.

Isocitrate Dehydrogenase (IDH) Inhibitors Market Company Landscape And Strategic Competition

Major companies operating in the isocitrate dehydrogenase (idh) inhibitors market are Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology Inc., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC

Access The Complete Isocitrate Dehydrogenase (IDH) Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/isocitrate-dehydrogenase-idh-inhibitors-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Isocitrate Dehydrogenase (IDH) Inhibitors Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (idh) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Size Of The Isocitrate Dehydrogenase (IDH) Inhibitors Market In 2026 And How Much Will It Reach By 2030?

The market size for isocitrate dehydrogenase (idh) inhibitors has seen substantial growth in recent years. It is anticipated to increase from $2.46 billion in 2025 to $3.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 26.8%. The expansion witnessed in previous periods can be attributed to developments in cancer genomics research, the existence of unmet oncology needs, innovations in mutation-driven drug discovery, the integration of these treatments within hospital oncology, and the enlargement of clinical trial initiatives.

The market size for isocitrate dehydrogenase (idh) inhibitors is anticipated to witness significant expansion in the upcoming years. It is projected to achieve a value of $8.02 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 26.6%. The expansion during the forecast period can be attributed to progress in precision medicine, biomarker-driven oncology treatments, rare cancer drug development pipelines, combination cancer therapies, and regulatory encouragement for targeted medications. Prominent trends for the forecast period include the broadening of targeted oncology treatments, increased development of drugs based on genetic mutations, a heightened focus on rare cancer therapy, greater utilization of precision oncology diagnostics, and developments in small molecule cancer inhibitors.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24577&type=smp

What Key Growth Drivers Are Influencing The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

The isocitrate dehydrogenase (IDH) inhibitors market is anticipated to expand, driven by the increasing incidence of acute myeloid leukemia. Acute myeloid leukemia (AML) is characterized as a rapidly progressing cancer of the blood and bone marrow, involving the swift production of abnormal white blood cells that hinder normal blood cell formation. The escalating frequency of acute myeloid leukemia is attributed to the growing aging population, as older individuals face a heightened risk of developing this aggressive blood cancer due to age-related changes in their bone marrow and immune system. Isocitrate dehydrogenase (IDH) inhibitors are utilized to treat acute myeloid leukemia by blocking mutant IDH enzymes, which helps restore normal blood cell development and decelerates the growth of leukemia cells. For example, a report released in February 2023 by the Australia-based non-profit organization, Leukaemia Foundation, predicted that from 2022 to 2035, over 7,000 children, 6,000 young adults, and 108,000 adults aged 25–65 are expected to be diagnosed with various blood cancers, primarily including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). Consequently, the rising occurrence of acute myeloid leukemia is set to propel the growth of the isocitrate dehydrogenase (IDH) inhibitors market.

What Are The Core Segment Classifications In The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

The isocitrate dehydrogenase (idh) inhibitors market covered in this report is segmented –

1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types

2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types

3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical

4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications

Subsegments:

1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma

2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)

3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers

Which Trends Are Supporting The Evolution Of The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

Leading companies in the isocitrate dehydrogenase (IDH) inhibitors market are prioritizing the attainment of regulatory approvals to broaden the clinical application of their treatments, expedite market entry, and establish a competitive edge in addressing IDH-mutant cancers. Regulatory approvals are official authorizations granted by health authorities, permitting a drug to be commercialized and utilized after its safety and effectiveness have been confirmed. For instance, in August 2024, Servier Laboratoires, a France-based pharmaceutical company, secured FDA approval for VORANIGO (vorasidenib) tablets as the first targeted therapy for patients with Grade 2 IDH-mutant glioma, including astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. This oral treatment significantly improves progression-free survival, as demonstrated in the Phase 3 INDIGO trial, where patients achieved a median progression-free survival of 27.7 months compared to 11.1 months for the placebo group. VORANIGO provides a convenient and well-tolerated option with manageable side effects, marking a crucial advancement for a patient group that previously had limited treatment alternatives.

Which Companies Are Influencing The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

Major companies operating in the isocitrate dehydrogenase (idh) inhibitors market are Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology Inc., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC

Access The Complete Isocitrate Dehydrogenase (IDH) Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/isocitrate-dehydrogenase-idh-inhibitors-global-market-report

Which Region Has The Strongest Presence In The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (idh) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Isocitrate Dehydrogenase (IDH) Inhibitors Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24577&type=smp

Browse Through More Reports Similar to the Global Isocitrate Dehydrogenase (IDH) Inhibitors Market 2026, By The Business Research Company

Histone Deacetylase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/histone-deacetylase-inhibitors-global-market-report

Metabolic Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report

Proton Pump Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/proton-pump-inhibitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Isocitrate Dehydrogenase (IDH) Inhibitors Market Expected To Change From 2026 To 2030?

The isocitrate dehydrogenase (idh) inhibitors market has seen substantial growth in recent years. It is anticipated to expand from $2.46 billion in 2025 to $3.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 26.8%. Historically, this growth can be ascribed to advancements in cancer genomics research, the pressing unmet needs in oncology, the rise of mutation-driven drug discovery, increasing hospital oncology adoption, and the expansion of clinical trials.

The isocitrate dehydrogenase (idh) inhibitors market is poised for significant expansion in the coming years. It is projected to achieve a value of $8.02 billion by 2030, growing at a compound annual growth rate (CAGR) of 26.6%. This anticipated growth is driven by advancements in precision medicine, biomarker-driven oncology care, the development of drugs for rare cancers, the adoption of combination cancer therapies, and regulatory support for targeted medications. Key trends expected during this forecast period include the broader application of targeted oncology treatments, an increase in drug development based on genetic mutations, a heightened focus on rare cancer therapies, the rising utilization of precision oncology diagnostics, and ongoing progress in small molecule cancer inhibitors.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24577&type=smp

What Factors Are Contributing To The Growth Of The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

The rising occurrence of acute myeloid leukemia (AML) is anticipated to fuel the expansion of the isocitrate dehydrogenase (IDH) inhibitors market in the future. AML is a rapidly progressing cancer affecting the blood and bone marrow, marked by the swift generation of abnormal white blood cells that hinder typical blood cell formation. The heightened incidence of AML stems from an increase in the elderly population, as older individuals are at a greater risk of developing this severe blood cancer due to age-related alterations in their bone marrow and immune system. Isocitrate dehydrogenase (IDH) inhibitors are effective in treating acute myeloid leukemia by inhibiting mutant IDH enzymes, thereby facilitating the restoration of normal blood cell development and slowing the proliferation of leukemia cells. For example, a report released in February 2023 by the Leukaemia Foundation, an Australia-based non-profit organization, projects that between 2022 and 2035, over 7,000 children, 6,000 young adults, and 108,000 adults aged 25–65 are expected to receive a diagnosis of blood cancers, mainly acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). Consequently, the growing frequency of acute myeloid leukemia is expected to propel the growth of the isocitrate dehydrogenase (IDH) inhibitors market.

Which Segments Define The Isocitrate Dehydrogenase (IDH) Inhibitors Market Segment Structure?

The isocitrate dehydrogenase (idh) inhibitors market covered in this report is segmented –

1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types

2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types

3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical

4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications

Subsegments:

1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma

2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)

3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers

What Trends Are Affecting The Growth Of The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

Leading companies in the isocitrate dehydrogenase (IDH) inhibitors market are prioritizing the attainment of regulatory approvals to expand the clinical utility of their therapies, expedite market entry, and secure a competitive advantage in addressing IDH-mutant cancers. Regulatory approvals are formal permissions granted by health authorities that permit a drug’s marketing and use after confirming its safety and effectiveness. A notable instance occurred in August 2024, when Servier Laboratoires, a France-based pharmaceutical company, received FDA approval for VORANIGO (vorasidenib) tablets. This marked its recognition as the first targeted therapy for patients with Grade 2 IDH-mutant glioma, encompassing astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. This oral treatment demonstrated a significant improvement in progression-free survival, as observed in the Phase 3 INDIGO trial, where patients had a median progression-free survival of 27.7 months compared to 11.1 months for those on placebo. VORANIGO offers a convenient and well-tolerated option with manageable side effects, representing a substantial advancement for a patient group that previously faced limited treatment choices.

Who Are The Established Players Within The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

Major companies operating in the isocitrate dehydrogenase (idh) inhibitors market are Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology Inc., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC

Get The Full Isocitrate Dehydrogenase (IDH) Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/isocitrate-dehydrogenase-idh-inhibitors-global-market-report

Which Region Is The Leading Market For The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (idh) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Isocitrate Dehydrogenase (IDH) Inhibitors Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/isocitrate-dehydrogenase-idh-inhibitors-global-market-report

Browse Through More Reports Similar to the Global Isocitrate Dehydrogenase (IDH) Inhibitors Market 2026, By The Business Research Company

Histone Deacetylase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/histone-deacetylase-inhibitors-global-market-report

Metabolic Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report

Proton Pump Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/proton-pump-inhibitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Isocitrate Dehydrogenase (IDH) Inhibitors Market By 2030 Starting From Its 2026 Size?

The market for isocitrate dehydrogenase (idh) inhibitors has experienced rapid expansion in its size over recent years. This market is projected to expand from $2.46 billion in 2025 to reach $3.13 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 26.8%. Historically, the growth witnessed in this sector can be ascribed to several factors, including advancements in cancer genomics research, the presence of unmet needs in oncology, the emergence of mutation-driven drug discovery, increased adoption within hospital oncology departments, and the expansion of clinical trials.

The market for isocitrate dehydrogenase (idh) inhibitors is projected to experience substantial expansion over the coming years. This market is anticipated to reach $8.02 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 26.6%. Factors contributing to this growth during the projected period include developments in precision medicine, oncology treatments guided by biomarkers, innovative drug pipelines for rare cancers, the emergence of combination cancer therapies, and robust regulatory backing for targeted medications. Key trends expected during the forecast timeframe encompass the wider adoption of targeted oncology therapies, an uptick in drug development based on genetic mutations, a heightened emphasis on treating rare cancers, the expanding application of precision oncology diagnostics, and progress in small molecule cancer inhibitors.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24577&type=smp

What Drivers Are Shaping The Future Growth Of The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

The rising incidence of acute myeloid leukemia is projected to stimulate the expansion of the isocitrate dehydrogenase (IDH) inhibitors market. Acute myeloid leukemia (AML) is defined as a rapidly advancing cancer of the blood and bone marrow, characterized by the quick proliferation of abnormal white blood cells that hinder regular blood cell formation. This increased occurrence of AML is attributed to the growing aging population, as older individuals are at a higher risk of developing this aggressive blood cancer due to age-related shifts in their bone marrow and immune system. Isocitrate dehydrogenase (IDH) inhibitors are effective in treating acute myeloid leukemia by blocking mutant IDH enzymes, thereby restoring normal blood cell development and slowing the growth of leukemia cells. For example, a report from the Australia-based non-profit Leukaemia Foundation in February 2023 indicated that from 2022 to 2035, over 7,000 children, 6,000 young adults, and 108,000 adults aged 25–65 are predicted to be diagnosed with blood cancers, primarily acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). Therefore, the increasing frequency of acute myeloid leukemia is expected to significantly drive the growth of the isocitrate dehydrogenase (IDH) inhibitors market.

Which Segment Categories Define The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

The isocitrate dehydrogenase (idh) inhibitors market covered in this report is segmented –

1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types

2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types

3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical

4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications

Subsegments:

1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma

2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)

3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers

What Major Market Trends Are Driving Changes In The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

Companies operating within the isocitrate dehydrogenase (IDH) inhibitors market are primarily focused on securing regulatory approvals. This strategy aims to broaden the clinical application of their therapies, hasten market entry, and gain a competitive edge in treating IDH-mutant cancers. Regulatory approvals represent official consent from health authorities, enabling a drug’s marketing and use after its safety and effectiveness are confirmed. For example, in August 2024, Servier Laboratoires, a pharmaceutical company based in France, received FDA approval for VORANIGO (vorasidenib) tablets. This marked its introduction as the first targeted therapy for patients diagnosed with Grade 2 IDH-mutant glioma, including astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. This oral treatment significantly extends progression-free survival, as demonstrated in the Phase 3 INDIGO trial, where patients experienced a median progression-free survival of 27.7 months compared to 11.1 months for those receiving placebo. VORANIGO provides a convenient and well-tolerated option with manageable side effects, representing a significant breakthrough for a patient population with previously limited treatment options.

Who Are The Top Companies Competing In The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

Major companies operating in the isocitrate dehydrogenase (idh) inhibitors market are Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology Inc., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC

Read the full isocitrate dehydrogenase (idh) inhibitors market report here:

https://www.thebusinessresearchcompany.com/report/isocitrate-dehydrogenase-idh-inhibitors-global-market-report

Which Geographic Regions Are Influencing Demand In The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (idh) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Isocitrate Dehydrogenase (IDH) Inhibitors Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24577&type=smp

Browse Through More Reports Similar to the Global Isocitrate Dehydrogenase (IDH) Inhibitors Market 2026, By The Business Research Company

Histone Deacetylase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/histone-deacetylase-inhibitors-global-market-report

Metabolic Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report

Proton Pump Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/proton-pump-inhibitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the isocitrate dehydrogenase (idh) inhibitors market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Isocitrate Dehydrogenase (IDH) Inhibitors Market from 2026 to 2030?

The market size for isocitrate dehydrogenase (idh) inhibitors has experienced rapid expansion over recent years. Projections indicate it will expand from $2.46 billion in 2025 to $3.13 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 26.8%. Historically, this growth has been driven by factors such as advancements in cancer genomics research, addressing unmet oncology needs, mutation-driven approaches in drug discovery, increased adoption in hospital oncology settings, and the expansion of clinical trials.

The isocitrate dehydrogenase (idh) inhibitors market is set to experience significant expansion over the next few years, with its valuation expected to reach $8.02 billion by 2030, demonstrating a robust compound annual growth rate (CAGR) of 26.6%. This projected growth throughout the forecast period can be attributed to advancements in precision medicine, the emergence of biomarker-driven oncology care, expanding rare cancer drug pipelines, the adoption of combination cancer therapies, and supportive regulatory environments for targeted drugs. Major developments anticipated during this timeframe include the broadening of targeted oncology treatments, an increase in drug development focused on genetic mutations, a heightened emphasis on treating rare cancers, the rising utilization of precision oncology diagnostics, and continued progress in small molecule cancer inhibitors.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24577&type=smp

What Drivers Are Affecting Demand In The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

The projected rise in acute myeloid leukemia cases is anticipated to drive expansion in the isocitrate dehydrogenase (IDH) inhibitors market. Acute myeloid leukemia (AML) is defined as a rapidly progressing blood and bone marrow cancer, marked by the swift generation of abnormal white blood cells that hinder typical blood cell development. The growing occurrence of acute myeloid leukemia stems from an increase in the elderly population, given that older individuals are more susceptible to this aggressive blood cancer owing to age-related alterations in their bone marrow and immune systems. Isocitrate dehydrogenase (IDH) inhibitors aid in treating acute myeloid leukemia by targeting and blocking mutant IDH enzymes, thereby facilitating the restoration of normal blood cell development and impeding the progression of leukemia cells. For example, a report from February 2023 by the Leukaemia Foundation, an Australia-based non-profit organization, projected that between 2022 and 2035, over 7,000 children, 6,000 young adults, and 108,000 adults aged 25–65 are forecast to receive diagnoses of blood cancers, mainly acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). Consequently, a rise in acute myeloid leukemia cases is expected to stimulate the expansion of the isocitrate dehydrogenase (IDH) inhibitors market.

Which Segment Groups Are Influencing The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

The isocitrate dehydrogenase (idh) inhibitors market covered in this report is segmented –

1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types

2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types

3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical

4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications

Subsegments:

1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma

2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)

3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers

Which Trends Are Expected To Influence The Isocitrate Dehydrogenase (IDH) Inhibitors Market In The Upcoming Years?

Key players within the isocitrate dehydrogenase (IDH) inhibitors market are prioritizing securing regulatory clearances to broaden the clinical application of their treatments, expedite their market introduction, and establish a competitive edge in addressing IDH-mutant cancers. These approvals denote formal authorizations issued by health agencies, permitting the commercialization and use of a drug once its safety and efficacy have been substantiated. An illustrative example is that in August 2024, Servier Laboratoires, a pharmaceutical firm based in France, obtained FDA approval for VORANIGO (vorasidenib) tablets, marking it as the initial targeted treatment specifically for individuals diagnosed with Grade 2 IDH-mutant glioma, encompassing astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. This orally administered medication substantially enhances progression-free survival, as demonstrated in the Phase 3 INDIGO trial, where patients achieved a median progression-free survival of 27.7 months compared to 11.1 months for those on placebo. VORANIGO presents a convenient and well-tolerated choice, featuring manageable side effects, thereby representing a notable leap forward for patient populations that previously had restricted treatment alternatives.

Who Are The Prominent Global Companies Shaping The Isocitrate Dehydrogenase (IDH) Inhibitors Market Landscape?

Major companies operating in the isocitrate dehydrogenase (idh) inhibitors market are Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology Inc., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/isocitrate-dehydrogenase-idh-inhibitors-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (idh) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Isocitrate Dehydrogenase (IDH) Inhibitors Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24577&type=smp

Browse Through More Reports Similar to the Global Isocitrate Dehydrogenase (IDH) Inhibitors Market 2026, By The Business Research Company

Histone Deacetylase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/histone-deacetylase-inhibitors-global-market-report

Metabolic Disorders Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report

Proton Pump Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/proton-pump-inhibitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Isocitrate Dehydrogenase (IDH) Inhibitors Industry Expected To Reach By 2029, Starting From 2025 Levels?

The market for isocitrate dehydrogenase (idh) inhibitors has experienced exponential expansion in recent years. It is projected to grow from $1.94 billion in 2024 to $2.46 billion in 2025, at a compound annual growth rate (CAGR) of 27.0%. The expansion observed in prior periods can be attributed to an increased incidence of hematologic cancers, enhanced genetic profiling in oncology, the clinical success of targeted therapies, various precision medicine initiatives, and a rise in healthcare spending specifically within oncology.

The market size for isocitrate dehydrogenase (idh) inhibitors is projected to experience significant expansion over the coming years. It is forecast to reach $6.34 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 26.7%. This projected growth during the forecast period is attributable to supportive reimbursement policies, an increasing incidence of blood cancers, rising awareness among oncologists, the growing adoption of precision medicine, and an increase in healthcare infrastructure and oncology centers. Prominent trends for the forecast period include advancements in genomic and molecular diagnostics, collaborations and licensing deals, progress in drug delivery technologies, improvements in diagnostic technologies, and the development of combination therapies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24577&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Isocitrate Dehydrogenase (IDH) Inhibitors Industry?

The anticipated rise in acute myeloid leukemia cases is poised to drive the expansion of the isocitrate dehydrogenase (IDH) inhibitors market. Acute myeloid leukemia (AML) is a rapidly progressing blood and bone marrow cancer characterized by the swift production of abnormal white blood cells that interfere with typical blood cell formation. The increasing incidence of acute myeloid leukemia is attributed to the growing aging population, as older individuals face a heightened risk of developing this aggressive blood cancer due to age-related changes in their bone marrow and immune system. Isocitrate dehydrogenase (IDH) inhibitors play a crucial role in treating acute myeloid leukemia by blocking mutant IDH enzymes, which in turn helps restore normal blood cell development and slow the proliferation of leukemia cells. For instance, in February 2023, a report from the Leukaemia Foundation, an Australia-based non-profit organization, stated that from 2022 to 2035, more than 7,000 children, 6,000 young adults, and 108,000 adults aged 25–65 are expected to be diagnosed with blood cancers, primarily acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). This anticipated increase in acute myeloid leukemia frequency is therefore expected to significantly propel the growth of the isocitrate dehydrogenase (IDH) inhibitors market.

What Are The Primary Types Of Segments Analyzed In The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

The isocitrate dehydrogenase (IDH) inhibitors market covered in this report is segmented –

1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types

2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types

3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical

4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications

Subsegments:

1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma

2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)

3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers

Which Trends Are Impacting The Isocitrate Dehydrogenase (IDH) Inhibitors Market?

Companies actively involved in the isocitrate dehydrogenase (IDH) inhibitors market are concentrating on acquiring regulatory approvals. This strategy aims to broaden the clinical application of their treatments, accelerate their market entry, and establish a competitive edge in IDH-mutant cancer therapy. Regulatory approvals are formal authorizations granted by health authorities, allowing a drug to be commercialized and utilized after its safety and effectiveness have been confirmed. As an illustration, in August 2024, Servier Laboratoires, a pharmaceutical company based in France, secured FDA approval for VORANIGO (vorasidenib) tablets. This approval positioned it as the inaugural targeted therapy for patients diagnosed with Grade 2 IDH-mutant glioma, including astrocytoma and oligodendroglioma, which possess IDH1 or IDH2 mutations. This oral treatment demonstrated a substantial improvement in progression-free survival, as evidenced in the Phase 3 INDIGO trial, where the median progression-free survival for patients was 27.7 months, contrasting with 11.1 months for the placebo group. VORANIGO presents a convenient and generally well-tolerated option with manageable adverse effects, signifying a crucial progression for a patient population with restricted prior treatment alternatives.

Who Are The Top Performing Companies In The Isocitrate Dehydrogenase (IDH) Inhibitors Market In Recent Years?

Major companies operating in the isocitrate dehydrogenase (IDH) inhibitors market are Roche Holding AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology, Inc., Philogen S.p.A., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/isocitrate-dehydrogenase-idh-inhibitors-global-market-report

What Are The Regional Market Dynamics Impacting The Isocitrate Dehydrogenase (IDH) Inhibitors Industry?

North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (IDH) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Isocitrate Dehydrogenase (IDH) Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24577&type=smp

Browse Through More Reports Similar to the Global Isocitrate Dehydrogenase (IDH) Inhibitors Market 2025, By The Business Research Company

Histone Deacetylase Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/histone-deacetylase-inhibitors-global-market-report

Metabolic Disorders Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report

Proton Pump Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/proton-pump-inhibitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model